Patents by Inventor Wing-pui Kong
Wing-pui Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250000968Abstract: Provided herein are nucleic acid molecules encoding a SARS-CoV-2 S ectodomain—HBsAg fusion protein. When expressed in mammalian cells (for example, by administration to a mammalian subject), the fusion protein self-assembles to form a HBsAg protein nanoparticle with SARS-CoV-2 S ectodomain trimers extending radially outward from an outer surface of the HBsAg protein nanoparticle. Thus, in several aspects, the disclosed nucleic acid molecule can be used to generate an immune response to SARS-CoV-2 in a subject.Type: ApplicationFiled: November 11, 2022Publication date: January 2, 2025Applicant: The United States of America, as represented by the Secretary,Department of Health and Human ServiceInventors: John Mascola, Cuiping Liu, Wei Shi, Amarendra Pegu, Lingshu Wang, Wing-Pui Kong
-
Patent number: 12172038Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: March 31, 2023Date of Patent: December 24, 2024Assignees: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20240299510Abstract: The present disclosure describes the grafting of epitope residues from human PCSK9 to non-human PCSK9 or PCSK9 structural homologs and elimination of 9-mers oligopeptides that are found in human protein to reduce self-targeting response. Anti-genicity of the epitope-scaffold constructs was demonstrated toward anti-human PCSK9 antibodies. similar to wild type human PCSK9. It was shown that disclosed PCSK9 immunogens could significantly reduce LDL and cholesterol levels in immunized mice.Type: ApplicationFiled: December 31, 2021Publication date: September 12, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Peter D. Kwong, Gwo-Yu Chuang, Baoshan Zhang, Wing-Pui Kong, Yiran Wang, Cara Chao, John R. Mascola, Li Ou, Tongqing Zhou, Yongping Yang, Bohan Liu, Cheng Cheng, Daniel W. Biner, Reda Rawi
-
Patent number: 12053519Abstract: Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: GrantFiled: September 23, 2019Date of Patent: August 6, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Peter Kwong, Li Ou, John Mascola, Baoshan Zhang, Kai Xu, Wing-Pui Kong, Yaroslav Tsybovsky, Cara W. Chao, Jeffrey Boyington, Yiran Wang
-
Publication number: 20240209032Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: ApplicationFiled: January 10, 2024Publication date: June 27, 2024Applicant: The United State of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Publication number: 20240150438Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: March 31, 2023Publication date: May 9, 2024Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Publication number: 20240101609Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: December 12, 2023Publication date: March 28, 2024Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servi, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Patent number: 11878998Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: GrantFiled: November 11, 2021Date of Patent: January 23, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Patent number: 11845778Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: GrantFiled: July 16, 2021Date of Patent: December 19, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20230338507Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: February 6, 2023Publication date: October 26, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
-
Patent number: 11780885Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: GrantFiled: November 15, 2017Date of Patent: October 10, 2023Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Kimberly Dowd, Barney S. Graham, Sung-Youl Ko, Wing-Pui Kong, John Mascola, Theodore Pierson, Mayuri Sharma, Dong Yu
-
Publication number: 20230242593Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: ApplicationFiled: September 16, 2022Publication date: August 3, 2023Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: KIMBERLY DOWD, BARNEY S. GRAHAM, SUNG-YOUL KO, WING-PUI KONG, JOHN MASCOLA, THEODORE PIERSON, MAYURI SHARMA, DONG YU
-
Publication number: 20230174587Abstract: Metapneumovirus (HMPV) F ectodomain trimers stabilized in a prefusion or postfusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the HMPV F ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HMPV in a subject. In additional embodiments, the therapeutically effective amount of the HMPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing HMPV infection.Type: ApplicationFiled: April 29, 2021Publication date: June 8, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Peter Kwong, Guillaume Stewart-Jones, Jason Gorman, Li OU, Tongqing Zhou, Baoshan Zhang, Wing-Pui Kong, Yaroslav Tsybovsky, John Mascola, Peter Collins, Ursula Buchholz
-
Patent number: 11602559Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: GrantFiled: October 3, 2017Date of Patent: March 14, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
-
Publication number: 20220356229Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: March 4, 2021Publication date: November 10, 2022Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Patent number: 11447541Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: September 20, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Patent number: 11370828Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: June 28, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20220064222Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: ApplicationFiled: November 11, 2021Publication date: March 3, 2022Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Publication number: 20220024987Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: July 16, 2021Publication date: January 27, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20210388066Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK